CONVENING NOTICE - EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB

Immunovia AB Sweden

no later than three weeks prior to the extraordinary general meeting. Copies of the documents will be sent upon request to shareholders providing their address to the Company and will be available at the general meeting. 

Information at the extraordinary general meeting 

The board and the CEO shall, if any shareholder so requests and the board believe that it can be done without material harm to the Company, provide information regarding circumstances that may affect the assessment of an item on the agenda and the Company's relation to other companies within the group. 

Processing of personal data  

For information on how your personal data is processed, see the privacy notice available on Euroclear's webpage, https://www.euroclear.com/dam/ESw/Legal/Privacy%20notice%20BOSS%20-%20final%20220324.pdf.  

Lund in October 2023 

Immunovia AB (publ) 

The board of directors 

For more information, please contact:
Jeff Borcherding, CEO
[e-mail] 

Karin Almqvist Liwendahl, CFO
[e-mail] 
[phone]

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com

CONTACT:

The following files are available for download:

https://mb.cision.com/Main/13121/3863976/2390429.pdf

Press release (PDF)

View original content:https://www.prnewswire.co.uk/news-releases/convening-notice---extraordinary-general-meeting-in-immunovia-ab-publ-301969900.html